Media Summary: In this segment, Raoul Tibes, MD, PhD, discusses risk stratification based on minimal residual disease A discussion by experts on the role of minimal residual disease ( Mark R. Litzow, MD; Aaron C. Logan, MD, PhD; and Bijal D. Shah, MD, provide a background on the current state of
Mrd Monitoring In Acute Lymphoblastic - Detailed Analysis & Overview
In this segment, Raoul Tibes, MD, PhD, discusses risk stratification based on minimal residual disease A discussion by experts on the role of minimal residual disease ( Mark R. Litzow, MD; Aaron C. Logan, MD, PhD; and Bijal D. Shah, MD, provide a background on the current state of Noelle Frey, MD, from the University of Pennsylvania, Philadelphia, PA, highlights the importance of minimal residual disease ... Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the results of a large-scale study evaluating the use of ... Selina M. Luger, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, discusses the current use of ...
The panelists, Raoul Tibes, MD, PhD; Stefan Faderl, MD; and Bijal D. Shah, MD, outline methods of measuring minimal residual ... Mark R. Litzow, MD; Aaron C. Logan, MD, PhD; Bijal D. Shah, MD; and Ryan D. Cassaday, MD, reflect on challenges presented ... It is important that current techniques for the Francesco Buccisano, MD, University of Rome Tor Vergata, Rome, Italy, discusses measurable residual disease (
